Page 4 - Bcli News Today

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Shares of BCLI stock opened at $3.02 on Tuesday. The stock has a market cap of $110.19 million, a P/E […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and Molecular Partners (NASDAQ:MOLN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Insider & Institutional Ownership 12.3% of Brainstorm Cell […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Profitability This table compares Brainstorm Cell Therapeutics and […]

Equities analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to announce earnings of ($0.13) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings of ($0.19) per share during the same quarter last year, which would […]

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, Dawson James reiterated a “neutral” rating on shares of Brainstorm Cell Therapeutics in a report on Wednesday, December 22nd. […]

Brokerages expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to post ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.13). Brainstorm Cell Therapeutics posted earnings per share of ($0.19) during […]

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report report published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Dawson James reissued a neutral rating on shares of Brainstorm Cell Therapeutics in a research note on Wednesday, December 22nd. NASDAQ:BCLI opened […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) released its earnings results on Monday. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.03, Fidelity Earnings reports. During the same period in the prior year, the firm posted ($0.37) earnings per share. Shares of NASDAQ:BCLI traded up […]